Abstract |
The efficacy of single- allergen-specific immunotherapy in polysensitized subjects is a matter of debate. We therefore performed a post hoc analysis of pooled data from six randomized, double-blind, placebo-controlled trials (N = 1871) comparing the efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet (AIT), Grazax (Phleum pratense 75 000 SQ-T/2800 BAU, ALK, Denmark), in mono- and polysensitized subjects. A statistically significant reduction in the mean total combined symptom/medication score (TCS) of 27% was demonstrated in actively treated subjects compared with placebo (P < 0.0001). This was not dependent on sensitization status (P = 0.5772), suggesting a similar treatment effect in mono- and polysensitized subjects (i.e. reductions of the TCSs of 28% and 26%, respectively, both P < 0.0001). Finally, a comparable and favourable safety profile of grass AIT was demonstrated in the two subgroups. Thus, no difference in efficacy and safety of single- allergen grass AIT was observed between mono- and polysensitized subjects.
|
Authors | H Nelson, M Blaiss, H Nolte, S Ø Würtz, J S Andersen, S R Durham |
Journal | Allergy
(Allergy)
Vol. 68
Issue 2
Pg. 252-5
(Feb 2013)
ISSN: 1398-9995 [Electronic] Denmark |
PMID | 23205670
(Publication Type: Comparative Study, Evaluation Study, Journal Article)
|
Copyright | © 2012 John Wiley & Sons A/S. |
Chemical References |
- Antigens, Plant
- Grazax
- Plant Extracts
- Tablets
|
Topics |
- Administration, Sublingual
- Adult
- Antigens, Plant
(immunology)
- Child
- Child, Preschool
- Desensitization, Immunologic
(methods)
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Male
- Patient Safety
- Phytotherapy
(methods)
- Plant Extracts
(therapeutic use)
- Poaceae
(immunology)
- Randomized Controlled Trials as Topic
- Rhinitis, Allergic, Seasonal
(drug therapy, immunology, physiopathology)
- Risk Assessment
- Severity of Illness Index
- Tablets
(administration & dosage)
- Treatment Outcome
|